Welcome to our dedicated page for Atara Biotherape news (Ticker: ATRA), a resource for investors and traders seeking the latest updates and insights on Atara Biotherape stock.
News about Atara Biotherapeutics, Inc. (NASDAQ: ATRA) centers on its development of allogeneic T-cell immunotherapies and the regulatory and business milestones associated with its Epstein-Barr virus (EBV)-specific platform. Atara describes itself as a leader in T-cell immunotherapy, focused on off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions, with headquarters in Southern California. Much of the company’s recent news flow has highlighted progress and challenges around tabelecleucel (tab-cel or EBVALLO), its EBV-specific T-cell therapy for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Investors following ATRA news can expect updates on FDA interactions, including Biologics License Application (BLA) submissions, Priority Review status, Prescription Drug User Fee Act (PDUFA) target action dates, and Complete Response Letters. Releases have detailed how Atara and its partner Pierre Fabre Laboratories addressed Good Manufacturing Practice (GMP) observations, transferred the tabelecleucel IND and BLA, and responded to evolving FDA positions on the adequacy of the pivotal ALLELE study for accelerated approval.
Company news also covers financial results and corporate restructuring, such as quarterly earnings releases, changes in research and development and general and administrative expenses, workforce reductions, lease amendments, and the impact of tabelecleucel-related milestone payments and commercialization revenue. In addition, Atara has issued updates on its strategic alternatives review, describing potential transactions it may consider to maximize shareholder value.
For readers tracking ATRA, this news stream provides insight into Atara’s clinical and regulatory trajectory, its partnership with Pierre Fabre Laboratories on tabelecleucel/EBVALLO, and the company’s evolving cost structure and strategic direction. Regularly reviewing these updates can help contextualize movements in ATRA stock and developments in the EBV-focused cell therapy space.
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, has announced that it will release its first quarter 2023 financial results after market close on Monday, May 8, 2023. The company specializes in developing transformative therapies for patients with cancer and autoimmune diseases, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform.
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) announced the grant of 93,950 restricted stock units to three newly hired employees, approved by the Compensation Committee of Atara’s Board of Directors. This grant, effective from April 3, 2023, is part of Atara's 2018 Inducement Plan and serves as an employment inducement under Nasdaq Listing Rule 5635(c)(4). The stock units will vest over four years, with 25% vesting after one year and the remainder in equal quarterly installments. Atara specializes in T-cell immunotherapy, developing therapies for cancer and autoimmune diseases.
Atara Biotherapeutics (NASDAQ: ATRA) has announced the grant of 62,350 restricted stock units to six new employees as an inducement to join the company. This award, approved by Atara's Compensation Committee, was granted under the 2018 Inducement Plan and will vest over four years, with 25% vesting on the first anniversary and the remaining vesting in 12 quarterly installments. Atara focuses on T-cell immunotherapy, developing treatments for cancer and autoimmune diseases using its EBV T-cell platform. The company aims to deliver off-the-shelf therapies to patients with significant needs.
Atara Biotherapeutics (NASDAQ: ATRA) announced its CEO, Pascal Touchon, will participate in a cell therapy panel at the Cowen 43rd Annual Health Care Conference on March 8, 2023, at 11:10 a.m. PST. The event will showcase the company's allogeneic Epstein-Barr virus (EBV) T-cell platform, aimed at developing therapies for cancer and autoimmune diseases. A live webcast will be available on Atara's website, with an archived replay accessible for 30 days post-event. Atara is at the forefront of T-cell immunotherapy, offering innovative treatments for serious diseases, including their lead program, tab-cel, which has received marketing authorization in Europe.
Atara Biotherapeutics, a leader in T-cell immunotherapy, announced that CEO Pascal Touchon will participate in a fireside chat at the H.C. Wainwright Cell Therapy Virtual Conference on February 28, 2023, at 12:00 p.m. PST. A live webcast of the presentation will be accessible on the company's website, with an archived replay available for 30 days. Atara is known for its innovative allogeneic Epstein-Barr virus (EBV) T-cell platform aimed at treating patients with serious diseases, including cancers and autoimmune disorders. The firm has advanced therapies such as tab-cel for EBV+ post-transplant lymphoproliferative disease and ATA188 for multiple sclerosis.
Atara Biotherapeutics (ATRA) reported its Q4 and full year 2022 financial results, announcing a net loss of $74.6 million for Q4 and $228.3 million for the year. The company successfully launched Ebvallo™ in Europe and has extended its cash runway into Q2 2024, with total cash and investments of $242.8 million as of December 31, 2022. Key upcoming events include the primary data readout from the Phase 2 EMBOLD study for ATA188 in October 2023. Atara has also engaged in discussions with the FDA regarding a potential BLA for tab-cel. The Chief Financial Officer is transitioning to Eric Hyllengren.
Atara Biotherapeutics has transferred the European Commission marketing authorization for EBVALLO™ (tabelecleucel), the only approved therapy for relapsed or refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), to Pierre Fabre. Starting immediately, Pierre Fabre will handle all commercialization activities in Europe, the Middle East, and Africa, with plans to launch in the first European countries by Q1 2023. EBVALLO™ is vital for patients with limited treatment options, offering a favorable risk-benefit profile based on pivotal Phase 3 study results. Atara retains rights in major markets like North America and Asia Pacific.
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, will release its fourth quarter and full year 2022 financial results on February 8, 2023, after market close. The company is recognized for its innovative allogeneic Epstein-Barr virus (EBV) T-cell platform, aimed at transformative therapies for patients with cancer and autoimmune diseases. Atara is making strides in creating off-the-shelf treatments, with a robust pipeline including tab-cel for EBV+ PTLD and ATA188 targeting multiple sclerosis. The company remains committed to enhancing patient lives through its advanced therapies.
Atara Biotherapeutics (NASDAQ: ATRA) recently granted restricted stock units totaling 36,750 shares and stock options for 48,300 shares to newly hired employees as part of its 2018 Inducement Plan. These awards were approved by the Compensation Committee and were granted to incentivize these new hires. The restricted stock units will vest over four years, while the stock options have a ten-year term with an exercise price of $5.13, reflecting the stock's closing price on February 1, 2023. Atara focuses on T-cell immunotherapy, particularly utilizing its EBV T-cell platform for treating serious diseases.
FAQ
What is the current stock price of Atara Biotherape (ATRA)?
What is the market cap of Atara Biotherape (ATRA)?
